August 14th 2025
The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
This Week in Managed Care: February 23, 2018
February 23rd 2018This week, the top managed care stories included the Trump administration proposed extending the duration of short-term health plans; a report found that CAR T-cell therapies are worth their high price tags; the new issue of Evidence-Based Oncology® examined current issues in immunotherapy.
Watch
Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say
February 22nd 2018Cell-free DNA derived from liquid biopsy offers the potential for minimally invasive genome-wide profiling of tumor alterations without tumor biopsy and can predict patient survival outcomes for patients with metastatic triple-negative breast cancer, according to a team of researchers.
Read More
With Approval of CAR T-Cell Therapy Comes the Next Challenge: Payer Coverage
February 22nd 2018CAR T- cell therapies are among the most expensive ever invented. For now, there’s a lot of uncertainty, as both government and commercial insurers, and a handful of the nation’s leading cancer centers, navigate a reimbursement structure that truly has no precedent.
Read More
Diminished Employment Participation After Breast Cancer Linked to Race and Insurance Status
February 22nd 2018African American patients and uninsured patients are more likely to have diminished employment participation 2 years after being cancer free than are those with no history of cancer, according to new research published in Cancer.
Read More
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
Read More
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21st 2018Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.
Read More
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21st 2018Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a new study published in Annals of Internal Medicine.
Read More
Recent Approval of Trastuzumab Biosimilar, Ogivri, Has Implications for Patients and Industry
February 21st 2018Last year's approval of trastuzumab biosimilar, Ogivri, will be the first competitor to blockbuster drug, Herceptin, for the treatment of HER2-positive breast cancer since its discovery.
Read More
The Clinical Trial and the Patient's Voice: "I'm Extremely Lucky to Be Alive"
February 21st 2018Two stories--of taking part in clinical trials, and of serving as a voice for patients among scientists who run them--highlight how the advances in cancer are built on the trust between those living with the disease and the clinicians on the frontiers of care.
Read More
Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
Read More
USPSTF Recommends Against Screening for Ovarian Cancer in Asymptomatic Women
February 18th 2018The US Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome because evidence shows that screening does not reduce ovarian cancer mortality.
Read More
Variation in Markups on Outpatient Oncology Services in the United States
Charges for oncology services vary widely across hospitals and impose financial burdens. Further legislation is needed to address disparities in access to high-quality cancer care.
Read More
Study Finds Merkel Cell Carcinoma Incidence Has Increased Since 2000
February 17th 2018Merkel cell carcinoma (MCC) is a rare disease, but it's getting less rare. Study results presented at the American Academy of Dermatology 2018 Annual Meeting found that cases of MCC increased 95% between 2000 and 2013
Read More
Pricing of Monoclonal Antibody Therapies: Higher If Used for Cancer?
The annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states.
Read More
Family History Associated With Breast Cancer Risk for Women 65 and Older
February 15th 2018First-degree family history was associated with an increased risk of breast cancer among women aged 65 and older, and risk associated with family history was not significantly modified by breast density, according to a study in JAMA Oncology.
Read More
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Read More
Pembrolizumab Associated With Increased Overall Survival in Patients With Urothelial Cancer
February 14th 2018There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
Read More
ASCO Review Finds Clinical Pathway Programs Adhere to Guidelines
February 13th 2018Last week, the American Society of Clinical Oncology (ASCO) published its review of the leading oncology pathway vendors in the United States in the Journal of Oncology Practice. The report found that overall, the prominent commercial pathway programs in the United States are aligned with ASCO’s evaluation criteria.
Read More
Kentucky's Medicaid Expansion Associated With Improved Breast Cancer Care
February 13th 2018Medicaid expansion in Kentucky led to an increase of screening mammograms, screening coverage, and breast-conserving surgery for women aged 20 to 64 with breast cancer, according to a study published in the Journal of the American College of Surgeons. However, the study also showed that time from diagnosis to operation increased post expansion and time from operation to chemotherapy remained unchanged.
Read More